BUSINESS● LOW1h ago · Sep 8, 2026, 5:54 PM
Beam drops after updating Phase 1/2 trial data for gene-editing drug
Seeking Alpha Tech · global
A company named Beam experienced a drop after updating Phase 1/2 trial data for its gene-editing drug. This indicates a significant development concerning the company's stock or project status in the biotechnology sector.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESS20m agoConsumer credit jumps past consensus in AugustSeeking Alpha TechBUSINESS27m agoHawaiian Electric started with Sell rating at Ladenburg Thalmann on persistent return degradationSeeking Alpha TechBUSINESS27m agoBitcoin flashes first golden cross in over 6 months as it hovers near $80KSeeking Alpha TechBUSINESS34m agoMiddle East conflict triggers 'ferocious' backwardation in oil marketsSeeking Alpha Tech